The anti-IgE mAb Omalizumab induces adverse reactions by engaging Fcγ receptors - Institut Pasteur Access content directly
Journal Articles Journal of Clinical Investigation Year : 2019

The anti-IgE mAb Omalizumab induces adverse reactions by engaging Fcγ receptors

Abstract

Omalizumab is an anti-IgE monoclonal antibody (mAb) approved for the treatment of severe asthma and chronic spontaneous urticaria. Use of Omalizumab is associated with reported side effects, ranging from local skin inflammation at the injection site to systemic anaphylaxis. To date, the mechanisms through which Omalizumab induces adverse reactions are still unknown. Here, we demonstrated that immune complexes formed between Omalizumab and IgE can induce both skin inflammation and anaphylaxis through engagement of IgG receptors (FcγRs) in FcγR-humanized mice. We further developed an Fc-engineered mutant version of Omalizumab, and demonstrated that this mAb is equally potent as Omalizumab at blocking IgE-mediated allergic reactions, but does not induce FcγR-dependent adverse reactions. Overall, our data indicate that Omalizumab can induce skin inflammation and anaphylaxis by engaging FcγRs, and demonstrate that Fc-engineered versions of the mAb could be used to reduce such adverse reactions.

Domains

Immunology
Fichier principal
Vignette du fichier
Balbino_OMA_JCI_MS_102319_revised_unmarked.pdf (2.78 Mo) Télécharger le fichier
Origin Files produced by the author(s)
Loading...

Dates and versions

pasteur-02451133 , version 1 (23-01-2020)

Identifiers

Cite

Bianca Balbino, Pauline Herviou, Ophélie Godon, Julien Stackowicz, Odile Richard-Le Goff, et al.. The anti-IgE mAb Omalizumab induces adverse reactions by engaging Fcγ receptors. Journal of Clinical Investigation, 2019, ⟨10.1172/JCI129697⟩. ⟨pasteur-02451133⟩
98 View
165 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More